Research findings last week included US vaccines maker Vaxcyte releasing highly impressive Phase III data for its VAX-31, for ...
Given the impact of the illegal medicines trade on public health in Latin America, on confidence in the health system and on ...
Leading Swiss contract development and manufacturing organization (CDMO) Lonza and Onava, a US biotech building an AI-native ...
US biopharma company Mineralys Therapeutics today announced the presentation of a new analysis from its pivotal Phase III ...
Israel-based Teva Pharmaceutical Industries US subsidiary today revealed that the US Food and Drug Administration (FDA) has ...
Iambic Therapeutics, the San Diego-based AI drug discovery company, has set terms for a Nasdaq initial public offering of 9,375,000 shares priced at $15 to $17 each, under the proposed ticker IAM, ...
Data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 showed that Eli Lilly’s ...
Belgo-Dutch immunology specialist argenx announced that it will discontinue the Phase III UNITY study of efgartigimod ...
US biotech Outlook Therapeutics, which is specializing in the development and commercialization of Lytenava (bevacizumab-vikg ...
India's pharmaceutical manufacturing industry is entering a delicate phase in its development. As uncertainty grows over its ...
When the World Health Organization (WHO) updates its Model List of Essential Medicines (EML), it gives governments a ...
Privately-held Endeavor BioMedicines said its Phase IIb WHISTLE-PF trial of taladegib (ENV-101) met its primary endpoint in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results